{"id":"trastuzumab-sc","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Musculoskeletal pain"}]},"_chembl":{"chemblId":"CHEMBL1201585","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Trastuzumab SC binds to the extracellular domain of the HER2/neu receptor, preventing dimerization and subsequent activation of downstream signaling pathways that promote cell growth and survival. This leads to inhibition of cancer cell growth and induction of apoptosis. Additionally, Trastuzumab SC can also induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), further contributing to its anti-tumor effects.","oneSentence":"Trastuzumab SC is a monoclonal antibody that targets the HER2/neu receptor, inhibiting cancer cell growth and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:57.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of HER2-positive breast cancer"},{"name":"Neoadjuvant treatment of HER2-positive breast cancer"},{"name":"Treatment of HER2-positive metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":360},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":"HER2 Positive Breast Cancer","enrollment":654},{"nctId":"NCT04253561","phase":"PHASE1","title":"Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2020-02-25","conditions":"Metastatic Breast Cancer","enrollment":17},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07470203","phase":"","title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":"HER2-positive Breast Cancer","enrollment":42},{"nctId":"NCT07413939","phase":"PHASE2, PHASE3","title":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","status":"NOT_YET_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-04-30","conditions":"HER2-positive Breast Cancer","enrollment":650},{"nctId":"NCT07214766","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2025-10-17","conditions":"Healthy Participants","enrollment":312},{"nctId":"NCT04893109","phase":"PHASE2","title":"ATEMPT 2.0: Adjuvant T-DM1 vs TH","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-16","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":500},{"nctId":"NCT04024462","phase":"PHASE3","title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT05730712","phase":"PHASE2","title":"Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-03-08","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":7},{"nctId":"NCT06876714","phase":"PHASE3","title":"ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-09-17","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage Breast Carcinoma","enrollment":1524},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT07299955","phase":"PHASE1","title":"A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Biocon Biologics UK PLC","startDate":"2026-01-09","conditions":"Healthy Male Participants","enrollment":150},{"nctId":"NCT05583110","phase":"PHASE2","title":"Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2023-03-08","conditions":"HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma","enrollment":13},{"nctId":"NCT04916002","phase":"PHASE2","title":"A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-11-30","conditions":"Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma","enrollment":77},{"nctId":"NCT03571633","phase":"PHASE2","title":"Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Leon Berard","startDate":"2018-08-06","conditions":"HER2-positive Breast Cancer, Operable Breast Cancer","enrollment":90},{"nctId":"NCT07245797","phase":"PHASE2","title":"A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC","status":"NOT_YET_RECRUITING","sponsor":"Zhimin Shao","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":164},{"nctId":"NCT04733118","phase":"PHASE2","title":"Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2021-08-05","conditions":"Early Breast Cancer","enrollment":393},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT04569747","phase":"PHASE2","title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-01-11","conditions":"HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer","enrollment":375},{"nctId":"NCT06027983","phase":"PHASE1, PHASE2","title":"Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2026-11-01","conditions":"HER2+ Advanced Breast Cancer, Other Solid Tumors","enrollment":36},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT04759248","phase":"PHASE2","title":"Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2021-03-15","conditions":"Breast Cancer","enrollment":55},{"nctId":"NCT05063786","phase":"PHASE3","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2021-09-14","conditions":"Advanced Breast Cancer","enrollment":27},{"nctId":"NCT02003209","phase":"PHASE3","title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-02-18","conditions":"HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7","enrollment":315},{"nctId":"NCT06172127","phase":"PHASE2","title":"PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-07-22","conditions":"HER2-positive Breast Cancer","enrollment":165},{"nctId":"NCT06687928","phase":"PHASE1","title":"To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2025-03-25","conditions":"Healthy","enrollment":200},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT05319873","phase":"PHASE1, PHASE2","title":"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2022-04-07","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":18},{"nctId":"NCT03161353","phase":"PHASE2","title":"Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2017-06-26","conditions":"Breast Cancer","enrollment":377},{"nctId":"NCT05955170","phase":"PHASE2","title":"Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2023-12-19","conditions":"HER2-positive Breast Cancer","enrollment":66},{"nctId":"NCT06835348","phase":"","title":"An Observational, Multicenter Study Evaluating the Safety of ReAl-lifePertuzumab and Trastuzumab Fixed Dose Combination: the RAPID Study","status":"COMPLETED","sponsor":"Fondazione Oncotech","startDate":"2023-10-03","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT05306041","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer","status":"RECRUITING","sponsor":"GBG Forschungs GmbH","startDate":"2023-01-02","conditions":"HER2-positive Breast Cancer","enrollment":170},{"nctId":"NCT04632992","phase":"PHASE2","title":"A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2021-01-13","conditions":"Advanced Unresectable or Metastatic Solid Malignancy","enrollment":252},{"nctId":"NCT05207722","phase":"PHASE1, PHASE2","title":"CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma","status":"TERMINATED","sponsor":"Celularity Incorporated","startDate":"2022-04-14","conditions":"Metastatic HER2 Positive Gastroesophageal Junction Cancer","enrollment":1},{"nctId":"NCT04675827","phase":"PHASE2","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2022-01-17","conditions":"HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer","enrollment":139},{"nctId":"NCT05824975","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2023-05-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)","enrollment":358},{"nctId":"NCT05275010","phase":"PHASE1","title":"A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-30","conditions":"Healthy Male Subjects","enrollment":151},{"nctId":"NCT03493854","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-06-14","conditions":"Early Breast Cancer","enrollment":500},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT03674112","phase":"PHASE2","title":"A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-12-19","conditions":"HER2-Positive Early Breast Cancer","enrollment":160},{"nctId":"NCT03329378","phase":"PHASE2","title":"Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-01-24","conditions":"Locally Advanced Breast Cancer","enrollment":7},{"nctId":"NCT01875367","phase":"PHASE3","title":"Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2013-09-18","conditions":"Breast Cancer","enrollment":166},{"nctId":"NCT03931551","phase":"PHASE2","title":"Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer","status":"TERMINATED","sponsor":"MedSIR","startDate":"2019-04-30","conditions":"Advanced Breast Cancer","enrollment":5},{"nctId":"NCT05091528","phase":"PHASE1, PHASE2","title":"A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers","status":"TERMINATED","sponsor":"Silverback Therapeutics","startDate":"2022-02-08","conditions":"HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer","enrollment":2},{"nctId":"NCT04395508","phase":"","title":"An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic","status":"APPROVED_FOR_MARKETING","sponsor":"Genentech, Inc.","startDate":"","conditions":"HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT05388500","phase":"PHASE3","title":"Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)","status":"NOT_YET_RECRUITING","sponsor":"Institut de cancérologie Strasbourg Europe","startDate":"2022-12-15","conditions":"HER2-positive Breast Cancer","enrollment":800},{"nctId":"NCT04856475","phase":"PHASE2","title":"Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2021-11-24","conditions":"Breast Cancer, Brain Metastases","enrollment":""},{"nctId":"NCT04296942","phase":"PHASE1","title":"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-04","conditions":"Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer","enrollment":1},{"nctId":"NCT03894007","phase":"PHASE2","title":"Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer","status":"TERMINATED","sponsor":"Renske Altena","startDate":"2019-05-23","conditions":"Early-stage Breast Cancer, HER2-positive Breast Cancer","enrollment":6},{"nctId":"NCT01566721","phase":"PHASE3","title":"A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-05-17","conditions":"Breast Neoplasms","enrollment":2577},{"nctId":"NCT01940497","phase":"PHASE3","title":"A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-15","conditions":"Breast Cancer","enrollment":240},{"nctId":"NCT03144947","phase":"PHASE2","title":"Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients","status":"UNKNOWN","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2016-11-29","conditions":"Cancer, Breast","enrollment":65},{"nctId":"NCT01810393","phase":"PHASE3","title":"A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-06-11","conditions":"Breast Cancer","enrollment":114},{"nctId":"NCT02568839","phase":"PHASE2, PHASE3","title":"Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2014-11","conditions":"Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer","enrollment":202},{"nctId":"NCT01959386","phase":"","title":"A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-07","conditions":"Breast Neoplasms","enrollment":1006},{"nctId":"NCT01926886","phase":"PHASE3","title":"A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-19","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT02402712","phase":"PHASE3","title":"Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05-06","conditions":"Breast Cancer","enrollment":418},{"nctId":"NCT02040935","phase":"PHASE3","title":"A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-02-21","conditions":"Breast Cancer","enrollment":128},{"nctId":"NCT02194166","phase":"PHASE3","title":"A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07-18","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT03058939","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2018-11","conditions":"Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III","enrollment":""},{"nctId":"NCT03881878","phase":"PHASE1, PHASE2","title":"TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2019-05-27","conditions":"HER2-positive Breast Cancer","enrollment":67},{"nctId":"NCT02019277","phase":"PHASE3","title":"A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-12-05","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT02738970","phase":"PHASE1","title":"A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-06-23","conditions":"Early Breast Cancer","enrollment":88},{"nctId":"NCT00944047","phase":"PHASE2","title":"Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2009-07","conditions":"Breast Cancer","enrollment":32},{"nctId":"NCT00194779","phase":"PHASE2","title":"Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery","status":"COMPLETED","sponsor":"University of Washington","startDate":"2003-10","conditions":"Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer","enrollment":50},{"nctId":"NCT00950300","phase":"PHASE3","title":"A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-16","conditions":"Breast Cancer","enrollment":596},{"nctId":"NCT00407888","phase":"PHASE2","title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-05","conditions":"Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IA Breast Cancer","enrollment":60},{"nctId":"NCT00088985","phase":"PHASE2","title":"Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2004-01","conditions":"Breast Cancer","enrollment":56},{"nctId":"NCT01401166","phase":"PHASE2","title":"Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-10","conditions":"Breast Neoplasms","enrollment":488},{"nctId":"NCT00800436","phase":"PHASE1","title":"A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT02658461","phase":"","title":"An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02","conditions":"Breast Cancer","enrollment":36},{"nctId":"NCT01928615","phase":"PHASE2","title":"A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT00006228","phase":"PHASE2","title":"Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-07","conditions":"HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer","enrollment":37},{"nctId":"NCT00028535","phase":"PHASE1","title":"Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-11","conditions":"Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Herceptin Hylecta","Herceptin-600 mg/5 mL","Herceptin","RO0452317"],"phase":"phase_3","status":"active","brandName":"Trastuzumab SC","genericName":"Trastuzumab SC","companyName":"Dana-Farber Cancer Institute","companyId":"dana-farber-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trastuzumab SC is an antibody used to treat various conditions, including inoperable, locally advanced or metastatic, ER-positive, and HER2-positive breast cancer. It is a biosimilar of the original Trastuzumab, with the same modality as an antibody.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}